Effectiveness of Qiliqiangxin Combined with Trimetazidine Hydrochloride Tablets in Treating Coronary Heart Disease with Concurrent Heart Failure: A Comparative Study

This study investigated the effect of combining qiliqiangxin with trimetazidine hydrochloride tablets in treating patients with coronary heart disease complicated by heart failure. A total of 158 patients were randomly divided into two groups: a control group with 79 patients who were given trimetazidine hydrochloride tablets and a study group, also comprising 79 patients who received qiliqiangxin capsules in addition to the tablets. Results showed that the study group had a higher total effective rate compared to the control group. After treatment, the study group exhibited a more significant decline in left ventricular end-systolic dimension and end-diastolic diameter, as well as a higher increase in left ventricular ejection fraction. Serum levels of N-terminal pro-B-type natriuretic peptide, cardiac troponin I, Angiotensin, interleukin-6, high-sensitivity C-reactive protein, and tumor necrosis factor-α were lower in the study group compared to the control group. Furthermore, the study group demonstrated a longer 6-minute walking distance and a lower incidence of adverse reactions. In conclusion, combining qiliqiangxin and trimetazidine hydrochloride tablets is highly effective and safe for treating coronary heart disease complicated with heart failure, improving clinical symptoms and heart function.